B7-H3 but not PD-L1 is involved in the antitumor effects of Dihydroartemisinin in non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

B7-H3 but not PD-L1 is involved in the antitumor effects of Dihydroartemisinin in non-small cell lung cancer

Published:2023-07 Issue: Volume:950 Page:175746
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Hu Bing-qi,Huang Jun-feng,Niu Ke,Zhou Jing,Wang Nan-nan,Liu Yu,Chen Li-wen

Funder

Natural Science Foundation of Anhui Province

Key Technologies Research and Development Program

Publisher

Elsevier BV

Subject

Pharmacology

Reference40 articles.

1. Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial;Aggarwal;J Immunother Cancer,2022

2. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics;Akinleye;J. Hematol. Oncol.,2019

3. B7-H3 expression in NSCLC and its association with B7-H4, PD-L1 and tumor-infiltrating lymphocytes;Altan;Clin. Cancer Res.,2017

4. Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy;Cai;Cell. Mol. Immunol.,2020

5. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer;Cai;Pharmacol. Res.,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Artemisinin and Its Derivatives as Potential Anticancer Agents;Molecules;2024-08-16

2. Induction of ferroptosis by natural products in non-small cell lung cancer: a comprehensive systematic review;Frontiers in Pharmacology;2024-05-01

3. From immune checkpoints to therapies: understanding immune checkpoint regulation and the influence of natural products and traditional medicine on immune checkpoint and immunotherapy in lung cancer;Frontiers in Immunology;2024-02-15

4. Immune checkpoints and cancer immunotherapies: insights into newly potential receptors and ligands;Therapeutic Advances in Vaccines and Immunotherapy;2023-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3